Mallinckrodt announced that the Food and Drug Administration (FDA) has granted Fast Track designation to the Investigational New Drug (IND) application of Synacthen Depot (tetracosactide) for the treatment of Duchenne muscular dystrophy (DMD).

Synacthen Depot is available outside of the U.S. for various autoimmune and inflammatory disorders. The company is currently evaluating the drug in a Phase 1 trial for the treatment of DMD in the U.S. 

Related Articles

Synacthen Depot is a long-acting depot formulation of tetracosactide, a synthetic 24 amino acid melanocortin receptor agonist. 

For more information visit